Editor David Collingridge discusses highlights from the April issue including: encouraging results from the START trials suggest fewer fractions of radiotherapy could revolutionise treatment of early stage breast cancer; how a phase II study investigating yttrium-90 labelled ibritumomab could have an important future role in the treatment of follicular non-Hodgkin lymphoma, and finally the pressing need for increased recruitment of adolescents and young adults in to cancer trials.

Dr David Collingridge, Editor of the Lancet Oncology, discusses highlights of the March issue in the first Lancet Oncology podcast. Two main topics are discussed: a research article highlighting how individuals in the United States who are under-insured or who have no medical insurance are at an increased risk of presenting with late-stage cancers; non-whites are at a similarly increased cancer risk. Also featured is a Dutch study showing the potential benefits of a shared-care programme between family doctors and oncology clinics for the long-term follow-up of individuals diagnosed with cancer in childhood.